Loading...
XLONMXCT
Market cap428mUSD
Dec 23, Last price  
327.00GBP
1D
-0.91%
1Q
6.17%
Jan 2017
137.82%
IPO
303.70%
Name

MaxCyte Inc

Chart & Performance

D1W1MN
XLON:MXCT chart
P/E
—
P/S
1,047.23
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.07%
Rev. gr., 5y
19.89%
Revenues
41m
-6.72%
5,059,5006,805,0007,164,4009,290,30012,269,50013,985,00016,667,00021,620,70026,168,90033,894,10044,261,50041,288,000
Net income
-38m
L+91.71%
-1,988,400-958,200-1,837,000-1,445,500-3,345,500-9,917,000-8,869,200-13,576,100-12,642,000-20,126,600-19,781,100-37,923,000
CFO
-22m
L+46.70%
-2,125,700-557,800-1,925,600-180,500-2,335,000-9,677,100-10,487,400-8,802,500-8,782,100-10,679,600-14,782,900-21,686,000
Earnings
Jun 11, 2025

Profile

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
URL
https://www.maxcyte.com/
IPO date
Mar 29, 2016
Employees
125
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
41,288
-6.72%
44,262
30.59%
33,894
29.52%
Cost of revenue
85,602
69,094
50,734
Unusual Expense (Income)
NOPBT
(44,314)
(24,833)
(16,840)
NOPBT Margin
Operating Taxes
(3,790)
1,044
Tax Rate
NOPAT
(44,314)
(21,043)
(17,884)
Net income
(37,923)
91.71%
(19,781)
-1.72%
(20,127)
59.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
269
2,888,500
236,077
BB yield
-0.06%
-520.17%
-25.57%
Debt
Debt current
1,548
157
527
Long-term debt
36,712
32,033
10,837
Deferred revenue
Other long-term liabilities
283
1,322
450
Net debt
(172,966)
(195,150)
(243,680)
Cash flow
Cash from operating activities
(21,686)
(14,783)
(10,680)
CAPEX
(3,700)
(18,477)
(3,834)
Cash from investing activities
54,984
(24,823)
(195,013)
Cash from financing activities
2,143
2,888
234,720
FCF
(42,206)
(50,609)
(25,060)
Balance
Cash
168,288
227,340
255,044
Long term investments
42,938
Excess cash
209,162
225,127
253,349
Stockholders' equity
(174,758)
(136,851)
(113,292)
Invested Capital
427,499
408,235
382,322
ROIC
ROCE
EV
Common stock shares outstanding
103,269
101,703
90,619
Price
4.70
-13.92%
5.46
-46.42%
10.19
525.15%
Market cap
485,362
-12.59%
555,297
-39.86%
923,408
715.53%
EV
312,396
360,147
679,729
EBITDA
(40,143)
(22,135)
(15,416)
EV/EBITDA
Interest
127
1,044
Interest/NOPBT